Kenneth C Valkenburg
Overview
Explore the profile of Kenneth C Valkenburg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
907
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verner E, Jackson J, Maddox C, Valkenburg K, White J, Occean J, et al.
J Mol Diagn
. 2025 Jan;
27(3):216-231.
PMID: 39818317
To help guide treatment decisions and trial matching, tumor genomic profiling is an essential precision oncology tool. Liquid biopsy, a complementary approach to tissue testing, can assess tumor-specific DNA alterations...
2.
Verner E, Jackson J, Severson E, Valkenburg K, Greer A, Riley D, et al.
J Mol Diagn
. 2023 Apr;
25(7):477-489.
PMID: 37068734
Genomic profiling is critical for precision oncology to guide treatment decisions. Liquid biopsy testing is a complementary approach to tissue testing, particularly when tissue is not readily available. The Labcorp...
3.
Ghiaur G, Valkenburg K, Esteb C, Ambinder A, Imus P, Pienta K, et al.
Cancer
. 2023 Feb;
129(11):1744-1751.
PMID: 36840972
Background: The bone/bone marrow is one of the most common sites for metastatic solid tumors. Moreover, the tumor microenvironment is an essential part of cancer homeostasis. Previously, it was shown...
4.
van t Erve I, Medina J, Leal A, Papp E, Phallen J, Adleff V, et al.
Clin Cancer Res
. 2022 Dec;
29(5):899-909.
PMID: 36534496
Purpose: Circulating tumor DNA (ctDNA) has the potential to guide therapy selection and monitor treatment response in patients with metastatic cancer. However, germline and clonal hematopoiesis-associated alterations can confound identification...
5.
Keefer L, White J, Wood D, Gerding K, Valkenburg K, Riley D, et al.
Nat Commun
. 2022 May;
13(1):2830.
PMID: 35595835
The lack of validated, distributed comprehensive genomic profiling assays for patients with cancer inhibits access to precision oncology treatment. To address this, we describe elio tissue complete, which has been...
6.
Deak K, Jackson J, Valkenburg K, Keefer L, Robinson Gerding K, Angiuoli S, et al.
J Mol Diagn
. 2021 Jul;
23(10):1324-1333.
PMID: 34314880
Genomic tumor profiling by next-generation sequencing (NGS) allows for large-scale tumor testing to inform targeted cancer therapies and immunotherapies, and to identify patients for clinical trials. These tests are often...
7.
van der Toom E, Axelrod H, de la Rosette J, de Reijke T, Pienta K, Valkenburg K
Nat Rev Urol
. 2018 Nov;
16(1):7-22.
PMID: 30479377
Despite improvements in early detection and advances in treatment, patients with prostate cancer continue to die from their disease. Minimal residual disease after primary definitive treatment can lead to relapse...
8.
Roy S, Axelrod H, Valkenburg K, Amend S, Pienta K
J Cell Biochem
. 2018 Nov;
120(4):4804-4812.
PMID: 30390333
Approximately 29 000 men die of prostate cancer (PCa) each year in the United States, and 90% to 100% of them are due to incurable bone metastasis. It is difficult...
9.
Axelrod H, Valkenburg K, Amend S, Hicks J, Parsana P, Torga G, et al.
Mol Cancer Res
. 2018 Oct;
17(2):356-369.
PMID: 30291220
Prostate cancer bone metastasis remains lethal and incurable, and often arises years after elimination of the primary tumor. It is unclear what underlies the decades-long clinical latency before recurrence, but...
10.
Axelrod H, Pienta K, Valkenburg K
Biol Proced Online
. 2018 Jul;
20:13.
PMID: 29988526
Background: Cancer metastasis is the primary cause of cancer-related deaths and remains incurable. Current clinical methods for predicting metastatic recurrence are not sensitive enough to detect individual cancer cells in...